Sutro Biopharma (STRO) had its price target raised by Citizens Jmp from $23.00 to $35.00. They now have a "market outperform" rating on the stock.
Sutro Biopharma (STRO) had its "outperform" rating reaffirmed by Citigroup Inc..
Sutro Biopharma (STRO) is now covered by Leerink Partners. They set an "outperform" rating and a $38.00 price target on the stock.
Sutro Biopharma (STRO) was upgraded by Truist Financial Corporation to "strong-buy".
Sutro Biopharma (STRO) had its price target raised by Deutsche Bank Aktiengesellschaft from $51.00 to $55.00. They now have a "buy" rating on the stock.